Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Notes Payables (2021 - 2023)

TriSalus Life Sciences has reported Notes Payables over the past 3 years, most recently at $1.6 million for Q2 2023.

  • For Q2 2023, Notes Payables rose 66.65% year-over-year to $1.6 million; the TTM value through Jun 2023 reached $1.6 million, up 66.65%, while the annual FY2022 figure was $944000.0, 73.53% up from the prior year.
  • Notes Payables for Q2 2023 was $1.6 million at TriSalus Life Sciences, up from $1.4 million in the prior quarter.
  • Over five years, Notes Payables peaked at $1.6 million in Q2 2023 and troughed at $544000.0 in Q4 2021.
  • A 3-year average of $1.0 million and a median of $944000.0 in 2022 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: soared 73.53% in 2022 and later surged 66.65% in 2023.
  • Year by year, Notes Payables stood at $544000.0 in 2021, then soared by 73.53% to $944000.0 in 2022, then surged by 66.65% to $1.6 million in 2023.
  • Business Quant data shows Notes Payables for TLSI at $1.6 million in Q2 2023, $1.4 million in Q1 2023, and $944000.0 in Q4 2022.